Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi by Matthew S. Painschab, Kate D. Westmoreland, Edwards Kasonkanji, Takondwa Zuze, Bongani Kaimila, Peter Waswa, Nader Kim El-Mallawany, Tamiwe Tomoka, Maurice Mulenga, Nathan D. Montgomery, Yuri Fedoriw, and Satish Gopal BloodAdv Volume 3(4):612-620 February 26, 2019 © 2019 by The American Society of Hematology

Matthew S. Painschab et al. Blood Adv 2019;3:612-620 © 2019 by The American Society of Hematology

Representative pathology from a patient with BL Representative pathology from a patient with BL. Hematoxylin and eosin stain demonstrates typical starry-sky appearance with a diffuse infiltrate of medium-sized lymphocytes and tingible-body macrophages (A), CD20 stains the malignant cells (B), CD10 stains the malignant cells (C), BCL2 is negative in the malignant cells and stains positive in background T lymphocytes (D), TdT is negative (E), and Ki67 is positive (F) in >95% of malignant cells. Representative pathology from a patient with BL. Hematoxylin and eosin stain demonstrates typical starry-sky appearance with a diffuse infiltrate of medium-sized lymphocytes and tingible-body macrophages (A), CD20 stains the malignant cells (B), CD10 stains the malignant cells (C), BCL2 is negative in the malignant cells and stains positive in background T lymphocytes (D), TdT is negative (E), and Ki67 is positive (F) in >95% of malignant cells. Magnification ×40 for all images. Matthew S. Painschab et al. Blood Adv 2019;3:612-620 © 2019 by The American Society of Hematology

Flowchart of first-line chemotherapy and outcomes among newly diagnosed patients with BL in Lilongwe, Malawi. Flowchart of first-line chemotherapy and outcomes among newly diagnosed patients with BL in Lilongwe, Malawi. Matthew S. Painschab et al. Blood Adv 2019;3:612-620 © 2019 by The American Society of Hematology

Kaplan-Meier curves for OS Kaplan-Meier curves for OS. OS curves shown for entire cohort (with 95% CI bands) (A), by HIV status (B), by aaIPI (C), and by treatment (CHOP vs more intensive regimens) (D). Kaplan-Meier curves for OS. OS curves shown for entire cohort (with 95% CI bands) (A), by HIV status (B), by aaIPI (C), and by treatment (CHOP vs more intensive regimens) (D). Matthew S. Painschab et al. Blood Adv 2019;3:612-620 © 2019 by The American Society of Hematology